New Retina Radio By Eyetube

In this roundtable hosted by María H. Berrocal, MD, and Audina M. Berrocal, MD, new department chairs in retina share their journeys to leadership and how to move the needle on diversity in the field. Participants include Sophie J. Bakri, MD, MBA; R.V. Paul Chan, MD, MSc, MBA, FACS; and Shlomit Schaal, MD, PhD, MHCM.  This editorially independent podcast is supported with advertising.

Aleksandra Rachitskaya, MD, moderates a panel comprised of Mrinali Gupta, MD; Eric Nudleman, MD, PhD; and Aris Thanos, MD, to review a study from the DRCR Retina Network that compared intravitreal aflibercept (Eylea, Regeneron) to vitrectomy with panretinal photocoagulation for the treatment of vitreous hemorrhage secondary to proliferative diabetic retinopathy. The group summarizes the study and weighs how its findings could affect clinical practice.  This editorially independent podcast is supported with advertising.

Aleksandra Rachitskaya, MD, leads a discussion with Mrinali Gupta, MD; Eric Nudleman, MD, PhD; and Aris Thanos, MD, about the phase 2 LADDER study, which evaluated the Port Delivery System With Ranibizumab (Genentech) in patients with wet AMD. Listen to a summary of the study and a thorough discussion of its implications with this group of Vit-Buckle Society members.  This editorially independent podcast is supported with advertising.

In this podcast, Prof. Richard Harrad (UK) joins Prof. Ben Thompson (Canada) and Prof. Ann Webber (Australia) for a discussion on the use of dichoptic therapy in the management of amblyopia. In this episode, we consider the limitations of the current clinical approach to amblyopia before discussing dichoptic therapy, a new and innovative technology with the potential to address some of the unmet needs in the management of this common condition. The faculty review the available evidence for dichoptic therapy, its potential benefits, the challenges associated with its use and how these might be overcome. This editorially independent podcast is supported with advertising.

In this podcast, Dr Peter Kaiser (USA) leads a conversation with Prof. James Wolffsohn (UK) and Dr Pearce Keane (UK) in which they explore the use of AI technology in clinical practice and how it may lead to changes in the management of patients. Considering both the front and the back of the eye, the faculty discuss current and potential future uses of AI in ophthalmology and optometry, the challenges associated with the development and integration of AI systems, and the benefits that may result from its use in eye care. This editorially independent podcast is supported with advertising.

Will data shared at AAO 2020 affect your clinical decision-making with wet AMD patients? Rishi Singh, MD, invites Justis Ehlers, MD, and Mark Gillies, MD, PhD, to review their presentations from AAO 2020 and discuss how clinical practice may be affected by their new information. Dr. Ehlers presented data on fluid volatility and the software used to measure it, and Dr. Gillies examined a 10-year data set of real-world wet AMD patients. This editorially independent podcast is supported with advertising.

Join Dr. Rishi Singh (USA) as he speaks with Prof. Jennifer Arnold (Australia), Prof. Mark Gillies (Australia) and Dr. SriniVas Sadda (USA) about the role and importance of fluid in the management of retinal diseases. In this episode, we will look at the different fluid compartments and our current understanding of their relevance to neovascular AMD. We will discuss the learnings gained from the HARBOR and FLUID clinical trials and the Fight Retinal Blindness! project, and consider key questions such as whether fluid can be protective and which types of fluid need to be treated aggressively. This editorially independent podcast is supported with advertising.

Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, review real-world data that compare widefield swept-source OCT angiography with ultra-widefield color fundus photography and fluorescein angiography for the detection disease activity in patients with diabetic retinopathy. This editorially independent podcast is supported with advertising.

Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, discuss a retrospective study on the efficacy and safety of an intravitreal dexamethasone implant (Ozurdex, Allergan) in patients with diabetic macular edema. They review the top-line data and study design of this real-world report. This editorially independent podcast is supported with advertising.

How will data shared at AAO 2020 impact clinical decision-making in wet AMD therapy? Rishi Singh, MD, is joined by Diana Do, MD, and Jeffrey Heier, MD, to review their talks from the AAO 2020 meeting and to see how their data might influence the day-to-day work of clinicians in retina. Dr. Do presented a meta-analysis comparing all anti-VEGF agents and regimens for the treatment of wet AMD, and Dr. Heier examined baseline patient characteristics in HAWK/HARRIER to have a better understanding of IOI events.  This editorially independent podcast is supported with advertising.

DRCR Retina Network Protocol AB compared aflibercept (Eylea, Regeneron) to PPV and PRP in patients with diabetic vitreous hemorrhage. DRCR Retina Network Vice Chair and Protocol AB chair Andrew Antoszyk, MD, joins NRR to review the study’s findings, which were presented at this year’s AAO Annual Meeting.  This editorially independent podcast is supported with advertising.

Tracking real-world data on geographic atrophy has been patchwork process—until now. Thanks to the AAO IRIS Registry, real-world information on eye diseases can be gathered and assessed. What was found in the IRIS Registry regarding GA, and how will it change the way you practice? Ehsan Rahimy, MD, outlines how he and his team identified patients and trends, and summarizes how he applied the group’s findings to his practice. Dr. Rahimy presented data from this discussion during this year’s AAO Annual Meeting Late Breakers session.  This editorially independent podcast is supported with advertising.

In 2021, E/M codes will undergo their most significant changes since 1997. How will these changes affect your billing and coding—and what processes can you put in place to get ahead of the game? AAO Coding and Practice Management Executive Joy Woodke informs us of the changes ahead, which were shared at this year’s AAO Annual Meeting.  This editorially independent podcast is supported with advertising.

The next generation of therapy for DME patients will require looking beyond the VEGF pathway. In the phase 2 BOULEVARD study, researchers are assessing the safety and efficacy of the angiopoietin-2 mediator faricimab (Roche/Genentech) for the treatment of DME. Could the angiopoietin pathway present a new option for patients? Karl Csaky, MD, PhD, sits down with NRR to review data from the study, which were shared at this year’s AAO Annual Meeting Late Breakers session.  This editorially independent podcast is supported with advertising.

Retinal arteriolar macroaneurysm (RAM) usually regresses spontaneously, but can lead to irreversible vision loss if regression does not occur. Could anti-VEGF therapy be an option for these patients? J. Fernando Arevalo, MD, PhD, joins NRR to discuss data from a study that asked that question. He presented the data at this year’s AAO Annual Meeting.  This editorially independent podcast is supported with advertising.

The burden of anti-VEGF therapy is particularly high in DME patients, many of whom are young, in the workforce, and unable to easily maintain monthly therapy. Could the antibody biopolymer conjugate KSI-301 (Kodiak Sciences) alleviate that burden while maintaining the outcomes experienced with anti-VEGF therapy? Arshad M. Khanani, MD, MA, shares the results of the phase 1B, long-term, multidose study that was presented at this year’s AAO Annual Meeting Late Breakers session. This editorially independent podcast is supported with advertising.

In episode 2 of the NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data,” Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution?  This editorially independent podcast is supported with advertising.

This NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” continues as Dr. Khanani and the roundtable participants Drs. Fuller, London, and Weng review the wet AMD pipeline with a focus on anti-Ang-2 therapy (faricimab, Roche/Genentech) and gene therapy (RGX-314, RegenxBio and ADVM-022, Adverum Biotechnologies). After the break, Dr. London shares the case of a patient with wet AMD who experienced a ceiling of response to anti-VEGF therapy. Did a switch to brolucizumab (Beovu, Novartis) result a change?  This editorially independent podcast is supported with advertising.

NRR’s miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” wraps up with moderator Dr. Khanani and panelists Drs. Fuller, London, and Weng discussing safety data. How have safety considerations changed in the wet AMD treatment landscape, and how do clinicians balance the risks and rewards of switching to a new agent? Additionally, Dr. Khanani closes out the series with the case of a patient whose disease stopped responding after a decade of anti-VEGF therapy. Listen here to learn how he approached the case.  This editorially independent podcast is supported with advertising.

Arshad M. Khanani, MD, MA, leads a roundtable consisting of Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA, as they discuss the art of drug choice in wet AMD therapy. The panel discusses how and why they switch therapy in challenging wet AMD cases and reviews how the COVID-19 pandemic has factored into their treatment algorithms. Also, Dr. Fuller shares the case of a wet AMD patient whose waning response to traditional therapy required intervention with an intravitreal dexamethasone implant (Ozurdex, Allergan).  This editorially independent podcast is supported with advertising.